From Disruption To Reinvention: The Story OfAPI-In-Capsule Technology And Its Future

By Dave Miller, CSO, AustinPx, Derek Hennecke, CEO, Grand River Aseptic Manufacturing, Tom French, Head of Process Technology, 3P innovation

First conceived in the early 2000s, API-in-capsule (AIC) technology, originally known as Xcelodose, was a disruptive innovation designed to remove traditional formulation steps and deliver active pharmaceutical ingredients (API) directly to patients. Early challenges, including a lack of scalability and market resistance, limited its initial adoption.

Despite early setbacks, AIC technology has been reinvented, providing a new path forward for pharmaceutical development and manufacturing. The next generation of AIC technology leverages modern automation and analytics to overcome previous limitations, enabling faster throughput and exceptional accuracy. The Fill2Weight technology, for example, utilizes a dual-phase gravimetric dosing algorithm that can accommodate a wide variety of powders and provides real-time adjustments to ensure consistent dosing. The technology is also proving to be a valuable tool for personalized medicine and dry powder inhalation, where therapies are often tailored to specific patient populations or genetic profiles.

Learn more about the story of AIC technology and its future in the full article.